Tourette Syndrome Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com

News provided by

RnR Market Research

Apr 14, 2015, 12:00 ET

Dallas, Texas (PRWEB) April 14, 2015 -- The report “Tourette Syndrome – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Tourette Syndrome. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tourette-syndrome-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. Companies discussed in this Tourette Syndrome – Pipeline Review, H1 2015 report include AstraZeneca PLC, Auspex Pharmaceuticals, Inc., Catalyst Pharmaceutical Partners, Inc., Edison Pharmaceuticals, Inc.,Neurocrine Biosciences, Inc., Otsuka Holdings Co., Ltd., Psyadon Pharmaceuticals, Inc., Reviva Pharmaceuticals Inc. and Synchroneuron Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are acamprosate calcium SR, aripiprazole, AZD-5213, CPP-115, dutetrabenazine ER, ecopipam hydrochloride, RP-5063, valbenazine, vatiquinone and vigabatrin. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310146 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: Jan 14, 2015: Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population 71, Oct 02, 2014: Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study 71, May 28, 2014: Psyadon Announces the Opening of a New Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome in Children Ages 7-17 72, Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome 73, Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854 74, May 11, 2011: Tourette Syndrome Association And Psyadon Pharma To Collaborate On Drug Trial For Tourette Syndrome Treatment 75, Dec 16, 2010: Otsuka Announces Defendants Appeal From Final Judgment In US Abilify Patent Litigation 75, Nov 16, 2010: Otsuka Prevails In US Abilify Patent Litigation 75 and Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial 76.

List of Tables

Number of Products under Development for Tourette Syndrome, H1 2015 8
Number of Products under Development for Tourette Syndrome - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Tourette Syndrome - Pipeline by AstraZeneca PLC, H1 2015 16
Tourette Syndrome - Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 17
Tourette Syndrome - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 18
Tourette Syndrome - Pipeline by Edison Pharmaceuticals, Inc., H1 2015 19
Tourette Syndrome - Pipeline by Neurocrine Biosciences, Inc., H1 2015 20
Tourette Syndrome - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 21
Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals, Inc., H1 2015 22
Tourette Syndrome - Pipeline by Reviva Pharmaceuticals Inc., H1 2015 23
Tourette Syndrome - Pipeline by Synchroneuron Inc., H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 32
Tourette Syndrome Therapeutics - Recent Pipeline Updates, H1 2015 51
Tourette Syndrome - Dormant Projects, H1 2015 69
Tourette Syndrome - Discontinued Products, H1 2015 70

List of Figures

Number of Products under Development for Tourette Syndrome, H1 2015 8
Number of Products under Development for Tourette Syndrome - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 13
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Top 10 Targets, H1 2015 26
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Explore more reports on Neurology therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]